** Shares of CSL CSL.AX fall as much as 5.5% to A$255.4, their lowest levels since November 21, 2023
** The biopharmaceutical co has reported half-year net profit of $2.01 billion, lower than analysts' forecast of $2.09 billion
** Co says earnings weighed down by falling immunisation rates in the U.S., its largest market
** About 1.2 million shares change hands, vs the 30-day average of 558,040
** Stock fell 1.8% in 2024
(Reporting by Nichiket Sunil in Bengaluru)
((Nichiket.Sunil@thomsonreuters.com;))
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。